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Abstract
Loss of synapse and synaptic dysfunction contribute importantly to cognitive impairment in 
Alzheimer’s disease (AD). Mitochondrial dysfunction and oxidative stress are early pathological 
features in AD-affected brain. However, the effect of AD mitochondria on synaptogenesis remains 
to be determined. Using human transmitochondrial “cybrid” (cytoplasmic hybrid) neuronal cells 
whose mitochondria were transferred from platelets of patients with sporadic AD or age-matched 
non-AD subjects with relatively normal cognition, we provide the first evidence of mitochondrial 
dysfunction compromises synaptic development and formation of synapse in AD cybrid cells in 
response to chemical-induced neuronal differentiation. Compared to non-AD control cybrids, AD 
cybrid cells showed synaptic loss which was evidenced by a significant reduction in expression of 
two synaptic marker proteins: synaptophysin (presynaptic marker) and postsynaptic density 
protein-95, and neuronal proteins (MAP-2 and NeuN) upon neuronal differentiation. In parallel, 
AD-mediated synaptic deficits correlate to mitochondrial dysfunction and oxidative stress as well 
as activation of p38 MAP kinase. Notably, inhibition of p38 MAP kinase by pharmacological 
specific p38 inhibitor significantly increased synaptic density, improved mitochondrial function, 
and reduced oxidative stress. These results suggest that activation of p38 MAP kinase signaling 
pathway contributes to AD-mediated impairment in neurogenesis, possibly by inhibiting the 
neuronal differentiation. Our results provide new insight into the crosstalk of dysfunctional AD 
mitochondria to synaptic formation and maturation via activation of p38 MAP kinase. Therefore, 
blockade of p38 MAP kinase signal transduction could be a potential therapeutic strategy for AD 
by alleviating loss of synapses.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and begins with a 
prominent impairment in cognitive function. At the early stage, patients with this devastating 
disease exhibit an inability to encode new memories of events or facts. Intact synaptic 
structure and function are essential for the synaptic encoding that forms stable memories [1, 
2]. While the molecular basis for early onset of AD is elusive [3], the structural and 
functional deficits in synapses are highly correlated with memory and cognitive impairment 
[4–7]. Given that synapse loss appears to be a morphological reflection of the synaptic 
dysfunction that begins earlier than amyloid-β (Aβ) plaque formation and neuronal loss [8], 
synaptic deficiency has been considered to be an early sign of AD [9–11]. Loss of pre-
synaptic or post-synaptic proteins, such as synaptophysin (presynaptic protein) [12] or 
postsynaptic density protein-95 (PSD95) [9], were demonstrated in early stage of AD 
transgenic mice and AD patients.
Mitochondrial dysfunction is well-known to associate with AD progression [13]. Aβ 
progressively accumulates in mitochondria and is associated with diminished enzymatic 
activity of respiratory chain complexes and a reduction in the rate of oxygen consumption 
[14, 15]. Cytoplasmic hybrid (“cybrid”) technology, with the transfer of mitochondria from 
affected patients to cell lines deficient in mitochondria (Rho0 cells), have been used to 
investigate the role of dysfunctional mitochondria in AD pathogenesis [16–18]. These 
human AD cybrid neuronal lines recapitulate mitochondrial structural and functional 
changes observed in AD-affected brains. AD cybrids reveal a decrease in cytochrome c 
oxidase, a key enzyme of respiratory chain, increased free radical production, impaired 
intracellular calcium buffering, fission-fusion imbalance, and decreased mitochondrial 
energy metabolism [17, 19–21]. Although AD cybrid cells can differentiate into a mature 
neuronal phenotype with the appearance of neuronal processes in the presence of 
staurosporine, 12-O-tetradecanoyl phorbol-13 acetate, their neuronal processes are shorter 
and less density as compared to non-AD differentiated cells [22]. Furthermore, differentiated 
AD cybrids exhibited mitochondrial defects, including disruption of mitochondrial 
respiration, aberrant energy metabolism, and significant reduction in mitochondrial 
transport, which was accompanied by increased mitochondrial oxidative stress. These are 
resembling characteristics of AD. It is unclear why and how neurons containing AD-derived 
mitochondria suffer synaptic pathology and a link of aberrant AD mitochondria to synaptic 
alteration remains to be determined.
AD transmitochondrial cytoplasmic hybrid (cybrid) neuronal cell lines with incorporated 
platelet mitochondria from sporadic AD or cognitively normal age-matched subjects [17, 
22–24] were used to model human AD-relevant mitochondrial function. We 
comprehensively evaluated the effect of mitochondrial dysfunction on synaptic development 
during the neuronal differentiation to address whether dysfunctional AD mitochondria 
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disturbs synaptogenesis and whether oxidative stress-mediated activation signaling 
potentiates the development of synapses, which links to mitochondrial abnormalities. Our 
results demonstrate that AD-affected mitochondria elicited detrimental effects on synaptic 
development via activation of p38 MAP kinase signaling pathway in AD cybrid cells. 
Inhibition of p38 MAP kinase activation blocked these detrimental effects. These studies 
explore a pivotal role of p38 MAP kinase pathway in mediating mitochondrial dysfunction 
and synaptic deficits in AD pathogenesis.
MATERIALS AND METHODS
Human subjects and creation of cybrid cell lines
Both AD patients and non-AD controls were recruited from the University of Kansas 
Alzheimer’s Disease Center (KUADC). Subjects with AD met the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association criteria [25]. This study was approved by the University of 
Kansas Medical Center (KUMC) Institutional Review Board. Non-AD subjects were 
cognitively normal and age-matched to AD subjects. All subjects provided written informed 
consent to participate in the study. The ages of AD and non-AD platelet donors were 73.6 
± 2.96 and 75.8 ± 5.04 years, respectively. The detailed information about gender, age, and 
disease status of donors is presented in Supplementary Table 1. All AD cases are sporadic 
and not due to APP/PS1/PS2 mutations, which do not show a clear Mendelian inheritance 
pattern, are essentially considered sporadic (i.e. they are not recognizably autosomal 
recessive or dominant). The mutation cases are incredibly rare, probably around 500 families 
in the world. Age of onset is usually in the 40 s or 50 s. They account for well less than 1% 
of AD cases. As long as a patient is >60 years old and does not have a parent who also 
developed AD before the age of 60, the chances of someone being Mendelian (rather than 
sporadic) is incredibly low. We do not have interest in making cybrids from mutation 
subjects because presumably the mitochondrial defects would be corrected in cell culture, 
since the mitochondria are separated from the presence of the nuclear mutation when we do 
the transfection into the Rho0 cells.
Cybrid cell lines were created on the human neuroblastoma cell (SH-SY5Y) nuclear 
background (by the KU ADC Mitochondrial Genomics and Metabolism Core) [26]. There 
are several reasons to select SH-SY5Y cells to create AD cybrid cells: 1) They are a 
commonly used human neuronal line and available in the laboratory when we decided to 
generate human neuronal cybrid cell line and 2) they can be differentiated into neuronal-like 
cells. Importantly, SH-SY5Y cells has been very successfully transmitted by mitochondria 
derived from human AD and non-AD subject as a human AD cybrid cell lines that 
recapitulate specific AD mitochondriopathies [17, 18, 22, 24, 27]. To create the cybrid cell 
lines used for this study, SH-SY5Y cells that were previously depleted of endogenous 
mtDNA (Rho0 cells), which were fused with platelet cytoplasm from human subjects, and 
repopulated with mitochondria containing mtDNA from patients or controls as previously 
described [28]. The quantitative real-time PCR showed that the intact mtDNA copies were 
present in all cybrids without detectable large scale deletion after many passages of cell 
proliferation as previously described [22].
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Cybrid growth and differentiation
AD and non-AD cybrid cells were grown in T75 tissue culture flasks in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% characterized fetal bovine 
serum (FBS; Gibco BRL, Logan, Utah), 100 μg/ml pyruvate, 50 μg/ml uridine, antibiotic-
antimycotic,100 Units/ml penicillin G, and 100 μg/ml streptomycin as previously described 
[17]. Culture media were replaced to the differentiation media [neurobasal media 
supplemented with 1× B27 (Invitrogen, Carlsbad, CA) and 0.5 mM glutamine, and 
antibiotic-antimycotic] with 10 nM staurosporine (SAT, Sigma-Aldrich Corp, St. Louis, 
Missouri, USA). Half of the differentiation media were made fresh with 10 nM SAT and 
replaced every day as previously described [22]. To assess the effects of the inhibitor of p38 
on cybrid cells, 1 μM SB203580 (EMD Chemicals, Inc.) were added to the media 30 min 
before replaced by differentiation media and also keep the SB203580 along with the 
differentiation. Based on the measurement of length of neuronal processes, day-14 cybrid 
cells reached plateau after differentiation in day-35 (data not shown), indicating that 
differentiation was completed on day 14 after SAT treatment.
Immunocytochemistry
Undifferentiated and differentiated cybrid cells cultured on coverslips, which were fixed in 
4% paraformaldehyde, and then permeability with 0.1%Triton X-100 in PBS. Cells were 
incubated in blocking solution (5% goat serum in PBS) for 20 min and then incubated with 
different primary antibodies: mouse anti-MAP2 (1:2000, #1284959, Chemicon), rabbit anti-
NeuN (1:1000, #ABN78, Chemicon), rabbit Anti-Synaptophysin (1:5000, #AB9272, 
Millipore), and mouse anti-PSD95 antibody (1:1000, #P246, Sigma), respectively, overnight 
at 4°C. After washing three times with PBS, cells were incubated with Alexa Fluor® 594 
conjugated goat anti-rabbit IgG or 488 goat anti-mouse IgG secondary antibodies at 1:1000 
dilutions for 2 h at room temperature. Fluorescence images were acquired using a Leica SP5 
confocal microscope and were analyzed with Leica LAS AF software (Leica Wetzlar).
Western blot analysis
Samples were lysed in extraction buffer [10 mM Tris-HCl (pH 7.4), 100 mM sodium 
chloride, 1 mM EDTA, 1 mM EGTA, 1 mM sodium fluoride, 20 mM sodium 
pyrophosphate, 2 mM sodium orthovanadate, 1% Triton X-100, 10% glycerol, 0.1% SDS, 
0.5% deoxycholate, 1 mM PMSF] containing protease inhibitor mixture (set V, EDTA-free; 
Calbiochem, San Diego, CA), separated by SDS/PAGE (12% Bis-Tris gel; Invitrogen), and 
then transferred to a nitrocellulose membrane (Amersham, Pittsburgh, PA). After blocking in 
TBST buffer (20 mM Tris-HCl, 150 mM sodium chloride, 0.1% Tween-20) containing 5% 
(wt/vol) nonfat dry milk (Santa Cruz) for 1 h at room temperature, the membrane was then 
incubated and gently shaken overnight (at 4°C) with a primary antibody. The primary 
antibodies were mouse anti-MAP2 (1:2000, #1284959, Chemicon), rabbit anti-NeuN 
(1:1000, #ABN78, Chemicon), rabbit anti-synaptophysin (syn, 1:5000, #AB9272, 
Millipore), mouse anti-PSD95 antibody (1:1000, # P246, Sigma), anti-phos-p38 (1:1000, 
#612288, BD), anti-total-p38 (1:1000, #9212, Cell signaling). The membranes were 
incubated for 2 h with horseradish (HRP)-conjugated secondary antibodies (SIGMA, USA) 
after washing with TBST three times. Final detection of immunoreactive bands was 
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performed by using enhanced chemiluminescence (Pierce™ ECL Western Blotting 
Substrate, Thermo Fisher, USA). Anti-mouse β-actin monoclonal antibody (Sigma-Aldrich, 
MO) at a 1:10,000 dilution was used to ensure equal protein loading of the samples.
Measurement of respiratory chain complexes enzyme activities and ATP levels
Enzyme complex IV (cytochrome c oxidase) activity, and ATP levels were determined as 
described previously [17]. Briefly, cybrid cells were washed with ice-cold PBS, and then 
harvested, centrifuged, and suspended in 50 μl of isolation buffer containing 250 mM 
sucrose, 20 mM HEPES, and 1 mM EDTA. Cell suspensions (containing ~3–4 mg of 
protein/ml) were added to a cuvette containing 0.95 ml of 1× assay buffer (10 mM Tris-HCl, 
and 120 mM KCl), and the reaction volume was brought to 1.05 ml with the addition of 1× 
enzyme dilution buffer (10 mM Tris-HCl, pH 7.0). The reaction was then initiated by the 
addition of 50 μl of ferrocytochrome substrate solution (0.22 mM). The rate of change in 
absorbance at 550 nm was recorded immediately using a Shimadzu (Kyoto, Japan) UV1200 
spectrophotometer programed for a 5-s delay and 10-s intervals for 6 readings. Data of 
cytochrome c oxidase activity are expressed as micromoles of cytochrome oxidized per min
−1 mg−1 protein using an extinction coefficient of 18.64 mM−1 cm−1. ATP levels were 
determined using an ATP Bioluminescence Assay Kit (Roche) following the manufacturer’s 
instruction as we previously described [29, 30]. Briefly, cells were quickly harvested by ATP 
lysis buffer, incubated on ice for 30 min, and then centrifuged at 12,000 g for 10 min. ATP 
levels were measured using a Luminescence plate reader (Molecular Devices). A 1.6-s delay 
time after substrate injection and 10 s integration time were used.
Evaluation of mitochondrial and intracellular reactive oxygen species (ROS)
Cybrid cells were seeded at low density onto Lab-Tek eight-well chamber slides (10000 
cells/well). Mitochondrial ROS generation was determined using MitoSox Red (Invitrogen), 
a unique fluorogenic dye highly selective for detection of superoxide production in live cell 
mitochondria. Cells were incubated with fresh medium containing 2.5 μM MitoSox for 30 
min. Fluorescence images were acquired using a Leica SP5 confocal microscope and 
analyzed using Leica LAS AF software (Leica Wetzlar). Excitation wavelengths were 543 
nm for MitoSox, and fluorescent signals were quantified using NIH Image J software.
Evaluation of intracellular ROS levels was assessed by election paramagnetic resonance 
(EPR) spectroscopy as described in our previous study [14, 31]. Cybrid cells cultured on 6-
well plates were washed with PBS and then incubated with CMH (Cyclic hydroxylamine 1-
hydroxy-3-methoxycarbonyl-2, 2, 5, 5-tetramethyl-pyrrolidine, 100 μM) at room 
temperature for 30 min. After that, cybrid cells were washed with ice-cold PBS, and then 
harvested with 100 μl of PBS for each well. EPR measurements were performed using a 
Bruker EMX plus X-band EPR spectrometer running Bruker Xenon acquisition/processing 
software and equipped with a dual mode cavity (ER4116DM) and Oxford ESR900 cryostat. 
For each sample ~50 μl was loaded into a 1.5 mm O.D. micropipette (Blaubrand 
intraMARK), sealed with Bruker X-Sealant and placed into a 4 mm O.D. EPR tube (Wilmad 
Labglass 707-SQ-250M). The EPR spectrometer was operated at 9.63 GHz and 100 kHz 
field modulation at room temperature. The spectra were recorded with the following 
parameters: number of scans, 3; magnetic field center, 344 mT; scan range, 10 mT; 
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microwave power, 2 mW; modulation amplitude, and 0.1 mT; time constant, 0.08 s. Signal 
intensity was determined as the height of the central peak on the up-field side of the 
midpoint.
Determination of mitochondrial membrane potential (ΔΨ) with TMRM
To detect mitochondrial membrane potential, cells were co-stained with TMRM (100 nM; 
Invitrogen) for 30 min. Mitochondria were labeled with Mito-tracker Red (MTRed, 100 nM, 
Invitrogen) and/or MitoTracker Green without interference of mitochondrial membrane 
potential (MTGreen, 100 nM, Invitrogen) for 30 min at 37°C before fixation to visualize 
mitochondrial morphology. To validate the specificity of TMRM dye, 10 μm carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) to collapse ΔΨ, and the obtained 
TMRM fluorescence was used to set the threshold.
Fluorescence images were acquired using a Leica SP5 confocal microscope and analyzed 
using Leica LAS AF software (Leica Wetzlar). Excitation wavelengths were 543 nm for 
TMRM or MTRed, and 488 nm for MTGreen, respectively. NIH Image J software for 
quantification of fluorescent signals and measurement of mitochondrial density.
Statistical analysis
Data are presented as mean ± SEM. Statistical analysis was performed using Statview 
software (SAS Institute, Version 5.0.1). Differences between means were assessed by one-
way analysis of variance (ANOVA) with Fisher posthoc test. p < 0.05 was considered 
significant.
RESULTS
Differentiation of AD and non-AD cybrid cells
Morphological changes were observed in non-AD (Fig. 1A II) and AD cybrid cells (Fig. 1A 
IV) treated with staurosporine (SAT) under serum free conditions. SAT, a chemical stimulus, 
serves as a particularly strong inducer of differentiation in the SH-SY5Y cells. The 
concentration of SAT between 4 and 25 nM has been used in a wide range of cells without 
toxic effect [32–34]. As such, we treated cybrid cells with 10 nM SAT for 14 days. 
Differentiated cells began to appear 3 days after SAT treatment and differentiation was 
complete on day 14. Over the course of a month, no cell detachment or apoptosis (based on 
stains to detect apoptosis) was observed. In the presence of 10 nM SAT for 14 days, a typical 
differentiated morphology was visualized as long and straight neuronal-like processes 
stretched out in the non-AD cybrid cells (Fig. 1A II). In contrast, differentiated AD cells 
revealed much shorter neuronal like processes than differentiated non-AD cells (Fig. 1A IV). 
Neuronal process length showed an almost 3-fold increase in differentiated non-AD cybrid 
cells compared to undifferentiated non-AD cells, whereas only a slight increase by 1.3-fold 
in the processes was observed in the differentiated AD cybrid cells compared to 
undifferentiated AD cybrid cells (Fig. 1B). There were no statistically significant difference 
in process length between the undifferentiated non-AD and AD cybrid cells; however, 
compared to differentiated non-AD cybrid cells, differentiated AD cybrid cells revealed 
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shorter neuronal-like processes, suggesting the impairment in the differentiation capacity of 
cybrid cells containing AD-derived mitochondria.
To further compare the difference between non-AD and AD cybrid cells in differentiation, 
we investigated the expression levels of neuronal markers in both cells with or without SAT 
treatment by immunoblotting and immunohistochemistry analyses. Microtubule-associated 
protein 2 (MAP2), a neuron-specific protein that stabilizes microtubules in the dendrites of 
postmitotic neurons, is widely used as a marker of neuronal differentiation [35]. Neuronal 
nuclear antigen (NeuN) appears highly specific as a marker of neuronal nuclei, also a marker 
of neuronal maturation [36]. Immunoblotting of cell lysates showed that MAP2 or NeuN 
levels were robustly elevated by ~10- or ~26-fold in differentiated non-AD cybrid cells 
compared to undifferentiated non-AD cells (Fig. 2A, B), suggesting a good capacity of 
differentiation in non-AD cybrid cells. However, MAP2 or NeuN levels were only increased 
by ~5- or ~12-fold in differentiated AD cybrid cells compared to undifferentiated AD cybrid 
cells, suggesting the impairment in the differentiation of AD-derived mitochondria. 
Consistent with immunoblotting results, immunoreactivity of MAP2 or NeuN was present in 
both differentiated non-AD and AD cybrid cells (Fig. 2E). There were significant reduced 
levels of MAP2 or NeuN immunoreactivity in differentiated AD cybrid cells compared to 
differentiated non-AD cybrid cells (4.6- versus 27-fold for MAP2 and 2.4-versus 5-fold for 
NeuN) (Fig. 2C–E). Overall, levels of MAP2 or NeuN in differentiated AD cybrid cells was 
significantly lower than that observed in differentiated non-AD cybrid cells. These data 
suggest that AD and non-AD cybrid cells have the capacity to differentiate neuronal like 
cells with axon-like neuronal process morphology. However, AD cybrid cells reveal the 
impairment in their capacity of differentiation into the neuronal like properties.
We next examined the effect of AD-derived mitochondria on synaptic protein expression and 
neuronal formation in AD cybrid cells compared to non-AD cybrid cells undergoing 
differentiation. The proper expression levels of the pre- and post-synaptic proteins, including 
synaptophysin and PSD95, were essential components for structure and function of synapses 
[37]. The differentiated non-AD cybrid cells induced by SAT demonstrated a robust increase 
in intensity of immunoreactive band for synaptophysin or PSD95 by 11- or 25-fold 
compared to undfferentiated non-AD cells (Fig. 3A). However, synaptophysin or PSD95 
levels were only increased by 1.5- or 3-fold in the differentiated AD cybrid cells in 
comparison with undfferentiated AD cybrid cells (Fig. 3A). Similarly, immunoreactivity of 
synaptophysin (red) or PSD95 (green) appeared in the differentiated non-AD and AD cybid 
cells with different fluorescence intensity. (Fig. 3D). Quantification of the intensity of 
immunofluorescence demonstrated significant increases in the fluorescence intensity of 
synaptophysin (Fig. 3B) and PSD95 (Fig. 3C) in differentiated non-AD and AD cybrid cells 
compared to either the undifferentiated non-AD cybrid cells (p < 0.01) or the AD cybrid 
cells (p < 0.01). Clearly, fluorescence intensity of synaptophysin or PSD95 was strikingly 
reduced by 5–6 fold in the differentiated AD cybrid cells compared to the differentiated non-
AD cells. In the representative immunostaining images, either synaptophysin or PSD95 were 
clearly visualized and evenly distributed along the differentiated processes of non-AD and 
AD cybrid cells, whereas both synaptic proteins were dramatically reduced in AD cybrid 
cells compared to non-AD cybrid cells upon differentiation (Fig. 3D). Accordingly, AD 
cybrids cells exhibit synaptic deficits evidenced by lower expression of synaptophysin and 
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PSD95, thus, impaired their ability to assembly full process lengths during neuronal-like 
differentiation.
Effect of p38 inhibitor on neuronal-like differentiation and development of synapses in AD 
cybrid cells
In view of significance on the activation of p38 MAP kinase in AD mitochondrial and 
synaptic alterations [24, 38, 39], we first assessed levels of the phosphorylation of p38 MAP 
kinase in this in vitro human cell upon differentiation by immunoblotting. The 
phosphorylation of p38 was robustly increased in AD cybrid cells compared to non-AD 
cybrid cells. Notably, treatment with a specific inhibitor of p38 (SB203580 1 μM) abolished 
p38 phosphorylation in AD cybrid cells compared to vehicle treatment. Similar blocking 
effect of p38 inhibitor was observed in non-AD cybrid cells (Fig. 4A). No significant change 
in total p38 was found in AD cybrid cells. Given that activation of p38 MAP kinase 
signaling pathway in AD-derived mitochondria might contribute to defective neuronal 
differentiation and synaptic structure and function, we sought to examine whether inhibition 
of p38 signaling pathway could ameliorate the pathologic events relevant to neuronal 
maturation in AD cybrid cells. AD cybrid cells were incubated with an inhibitor of p38, 
SB203580 1 μM, and then evaluated for neuronal morphology and synaptic protein 
expression in the presence of SAT to induce cell differentiation. In the presence of p38 
inhibitor, AD cybrid cells revealed significantly increased neuronal-like processes and length 
of processes (Fig. 4B, C) compared to vehicle-treated AD cells under normal differentiation 
condition with SAT. Accordingly, loss of neuronal markers for MAP2 and NeuN were 
completely restored in differentiated AD cybrid cells in the presence of SB203580 compared 
to the absence of SB203580 (Fig. 4D), in parallel, the expression of pre- and post-synaptic 
proteins, synaptophysin and PSD95, were also rescued in differentiated AD cybrid cells 
exposed to SB203580 compared with vehicle control cells (Fig. 4E). These results indicate 
the protective effect of blocking p38 activation on deficit in neuronal differentiation and 
synaptic formation insulted by AD mitochondria.
Effect of p38 inhibitor on mitochondrial oxidative stress and function
Given that oxidative stress is important for the activation of p38 MAP kinase and that 
mitochondria are a major source of ROS production, we next to determine a connection of 
mitochondrial oxidative stress to activation of p38 signals in AD-derived mitochondria. We 
first examined the effect of p38 on mitochondrial oxidative stress by determining 
mitochondria-derived ROS. Consistent with our previous observation, differentiated AD 
cybrid cells demonstrated a significantly increased ROS [22] compared to non-AD cybrid 
cells. MitoSox-Red signals, an indicator of mitochondrial superoxide, were greatly increased 
in differentiated AD cybrid cells in comparison with non-AD cybrid cells (Fig. 5A, B), 
suggesting increased levels of mitochondrial ROS in AD cybrid cells [22]. Treatment of p38 
inhibitor completely eliminated excessive MitoSox signals. There was no effect of p38 
inhibitor in non-AD cybrid cells compared to vehicle-treated control cells, suggesting 
nontoxic effect of p38 inhibitor SB203580 on cells. Furthermore, we quantitatively 
measured the intracellular ROS levels in the cells by highly sensitive and specific EPR 
spectroscopy. The intracellular ROS levels indicated by EPR peaks were significantly 
elevated in differentiated AD cybrid cells compared to non-AD cells. This was robustly 
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blocked by the addition of p38 inhibitor SB203580. These results suggest that blocking the 
activation of p38 MAP kinase reduces mitochondrial oxidative stress in AD-affected 
mitochondria.
Next, we evaluated mitochondrial function by examining mitochondrial respiratory chain 
activity, membrane potential, and ATP level. In response to SAT-induced differentiation, AD 
cybrid cells revealed decreases in cytochrome c oxidase activity, a key enzyme of complex 
IV in the respiratory chain, ATP levels, and TMRM as an indicator of mitochondrial 
membrane potential compared to non-AD cybrid cells. The addition of FCCP, an uncoupling 
mitochondrial membrane agent, abolished TMRM signals (Fig. 5H), indicating the specific 
reaction of TMRM as an indicator of mitochondrial membrane potential. Notably, treatment 
of p38 inhibitor SB203580 alleviated these detrimental effects in differentiated AD cybrid 
cells as shown by increased complex IV activity, ATP levels (Fig. 5E, F) and mitochondrial 
membrane potential (Fig. 5G, H). These data suggest that the inhibition of p38 MAP kinase 
activation ameliorates AD-specific mitochondrial dysfunction in the differentiated AD 
cybrid cells.
DISCUSSION
Oxidative stress, mitochondrial dysfunction, and synaptic loss are early features in the 
pathogenesis of AD. Abnormal mitochondrial permeability transition pore [29] and 
impairment in mitochondrial clearance such as inactivation of mitochondrial degrading 
enzyme cause accumulation of mitochondrial Aβ and potentiate aberrant mitochondria [14, 
40]. Interaction of Aβ with mitochondrial protein enhances ROS production and 
accumulation, which in turn triggers opening of mPTP and release mitochondrial protein 
(cytochrome C) to cytosol, leading to the activation of signal transduction such as p38 MAP 
kinase and apoptosis [15, 41–43]. In this study, we illustrated that AD-affected mitochondria 
act as a trigger for increasing levels of ROS, subsequently, elevated ROS promotes activation 
of p38 MAP kinase signaling pathway. One after another, the activated p38 MAP kinase 
critically contributes to neuronal differentiation impairment and synaptic deficits in AD 
cybrid cells via augmentation of mitochondrial oxidative stress and consequent amplification 
of mitochondrial dysfunction. Blockade of p38 MAP kinase signaling in AD cybrids by a 
pharmacological p38 inhibitor ameliorated AD-associated detrimental impacts 
aforementioned. Our findings highlighted a pivotal role of p38 MAP kinase signaling in 
mediating mitochondrial dysfunction and synaptogenesis in pathogenesis of AD (Fig. 6).
It has been demonstrated that ROS and phosphorylated p38 MAP kinase are significantly 
elevated in undifferentiated and differentiated AD cybrid cells compared to non-AD cybrids 
[17, 22, 24]. Activation of p38 MAP kinase is associated with increased ROS production/
accumulation and mitochondrial stress [39, 44–46] and contributes to synaptic dysfunction 
[47–49]. The antioxidant blocked p38 activation along with attenuating mitochondrial 
perturbation. Furthermore, the suppression of the p38 MAP kinase pathway also results in a 
prevention of oxidative stress-induced mitochondrial and cellular perturbation [39, 50]. 
Thus, increases in ROS generation in AD cybrid cells containing AD mitochondria could 
trigger activation of p38 MAP kinase signaling, which in turn exacerbate mitochondrial and 
neuronal dysfunction. Indeed, the suppression of ROS rescues mitochondrial function, 
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transport, and mitochondrial dynamics [17, 22]. Given the link of ROS to synaptic 
mitochondrial and synaptic alterations and the vital role of synaptic mitochondria in synaptic 
transmission [14, 22, 29, 30, 39, 51–55], we propose that AD-associated ROS production 
could directly or indirectly affect cell differentiation as shown by compromised synaptic 
development and formation of synapse in AD-derived mitochondria in response to chemical-
induced neuronal differentiation. Inhibition of excessive ROS and activation of p38 MAP 
kinase rescues impairment in synaptic development and formation of synapses as shown by 
increased expression levels of pre- and post-synaptic proteins.
The differentiation capacity of cybrid cells was noted and compared by measuring the 
expressions of neuronal markers such as MAP2 and NeuN. Previous studies have shown 
increased expressions of neuronal markers in neuronal SH-SY5Y cells under differentiation 
[56, 57]. It was report that staurosporine is capable of inducing apoptosis or cellular 
perturbation in neuron cells including SH-SY5 [58, 59], AF5 neural cells derived fetal rat 
mesencephalic tissue [60], rat hippocampus neurons [61], and human cortical neurons 
(HCN-1A) [62]. However, the concentration of staurosporine used for the experiments 
ranges from 250 nM to 10 μM, which is significantly higher than what we used in our 
differentiation system (10 nM). It is almost 25–1000 times higher than the concentration in 
our culture with staurosporine treatment in order to induce cellular dysfunction or apoptosis. 
MAP2 is an abundant neuronal cytoskeletal protein regulating the structure and stability of 
microtubules, and it is also employed as a marker for neuronal maturation [63]. We found 
that MAP2 levels were markedly increased in the differentiated non-AD cybrid cells, from 
their cell bodies to processes, in comparison with their undifferentiated status. Although the 
increase could be detected in the cellular bodies in the AD cybrid cells with SAT treatment, 
the elevation of these two neuronal proteins was insignificant in the impaired processes, 
indicating an ill-differentiation in the processes of AD cells. Consistent with our data, the 
numbers of MAP2 immunoreactive neurons were reported ~30% less in AβPP transgenic 
mice than nontransgenic mice at 2–3 months of age, well before Aβ plaque formation [64]. 
In addition, another marker of neuronal maturation, NeuN, which is present in nuclei of 
most neuronal cells throughout the nervous system of adult brain [65], increased expression 
could be found in the nuclei of both differentiated non-AD and AD cybrid cells compared 
with the levels of their undifferential status. However, a significant difference could be found 
between the differentiated non-AD and AD cells, suggesting that AD cybrids in 
differentiation was less matured than the non-AD cells, though AD cells could be induced to 
matured cell body with SAT treatment. The changes in the neuronal markers demonstrated 
that AD cybrids are less matured under differentiation, especially in the processes, where the 
AD cells have impaired expression of the neuronal markers. There are many other proteins, 
which have been found in the synapse that change their expression during the development 
and disease state, including proteins related to synaptic vesicle postsynaptic density and 
presynaptic active zone. Oxidative stress potentiates synaptic alterations relevant to the 
pathogenesis of AD [14, 29, 66]. Alteration in endophilin 1, a synaptic vesicle protein, has 
been found to associate with AD pathology [67].
Synaptic dysfunction and synapse loss contribute importantly to cognitive deficits of AD [4–
7]. Loss of synapses is one of the hallmarks of AD [68], and a better disease predictor than 
the amyloid plaque load [7]. As synaptic dysfunction begins early in the disease and is likely 
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reflected morphologically by synapse loss, the investigation of the link between synaptic 
function and cognitive decline has been extensively conducted in mouse models of AD or 
from post mortem human tissue samples [69–71]. Synaptic marker proteins, synaptophysin 
and PSD95, are essential components of synaptic structure and function [37]. Reduced 
expression of the synaptophysin, a presynaptic vesicle protein was reported in hippocampus 
and associated cortices of AD patients and was responsible for cognitive decline [7, 72, 73]. 
The density of synatophysin positive presynaptic terminals was reduced by ~30% in genetic 
human disease mice carrying mutant form of human AβPP and expression of human Aβ 
compared to nontransgenic mice at 2–3 months of age well before amyloid plaque formation 
[64]. Similarly, both mRNA and protein levels of postsynaptic protein PSD95 were 
markedly reduced in human AD-affected inferior temporal cortex of AD patients [74]. In 
corollary to this study, we demonstrated that the protein levels of synaptophysin and PSD95 
were robustly lower in the differentiated AD cybrid cells compared to the differentiated non-
AD cybrid cells, suggesting that reduction in expression of pre- and post-synaptic proteins, 
such as synaptophysin and PSD95, results in structural and functional alterations in synaptic 
maturation and development in AD cybrid cells upon abnormal neuronal differentiation. 
Owing to an essential energy-supplying organelles, mitochondria are particularly important 
to neuron metabolism, function, and neurotransmitter synthesis and transport [75]. 
Mitochondria distributed along neuronal dendrites actively participate in the morphogenesis 
and plasticity of spines and synapses [76–78]. Reduction in dendritic mitochondria leads to 
loss of synapses and number of dendritic spines, while increased dendritic mitochondrial 
content and mitochondrial activity improve plasticity of spines and synapses [78, 79]. 
Mounting evidence, including ours, has clearly demonstrated the early deficits in synaptic 
mitochondria in AD-affected brains, which correlate to synaptic loss [30, 80]. The effect of 
AD-associated mitochondrial defects on synaptogenesis remains to be determined. We 
previously demonstrated mitochondrial dysfunction in AD cybrids under “rest” or 
undifferentiated status [17]. Our recent study showed, after differentiation, AD cybrids 
demonstrated decreased mitochondrial function, lower mitochondrial membrane potential, 
deficits in AD mitochondrial transport, and significantly elevated mitochondrial oxidative 
stress along with a mal-differentiated status [22]. Moreover, the present study is to address 
whether AD-mediated mitochondrial dysfunction links to synaptic formation and 
maturation. In differentiated AD cybrids, synaptic loss was correlated to mitochondrial 
dysfunction and elevated mitochondrial oxidative stress. These findings are in agreement 
with those studies revealing the relationship between dendritic mitochondrial deficiency and 
synaptic loss in AD models. In view of the protective effect of antioxidant on mitochondrial 
function and ROS production/accumulation [14, 22, 31], increased mitochondrial oxidative 
could potentiate synaptic alterations. Indeed, our results show that abrogation of 
mitochondria ROS increases the formation of neurol process and the production of synaptic 
proteins in AD cybrid cells induced by SAT differentiation. The proper mitochondrial 
function are critical for mitochondrial dynamics by maintaining the balance of mitochondrial 
fission and fusion and synapse formation [17, 18, 81]. Excessive mitochondrial ROS causes 
imbalance of mitochondrial fission and fusion in mild cognitive impairment-and AD-
affected mitochondria. The suppression of overproduction of ROS rescues abnormal 
dynamics and mitochondrial transport [17, 18, 22]. Thus, AD-mediated the disruption of 
mitochondrial dynamics and mitochondrial trafficking could also be the possible mechanism 
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underling impairment in synaptic development and maturation. It requires further 
investigation to uncover the link of the imbalance of mitochondrial fission and fusion to 
synaptogenesis insulted by AD-affected mitochondria in AD cybrid cells under 
differentiated status.
The p38 MAP kinases are a family of serine/threonine protein kinases and involved in 
cellular responses to external stress signals. Phosphorylation of p38 MAP kinase occurred in 
response to oxidative stress such as hypoxia [82] and H2O2 administered exogenously [83]. 
Accumulating evidence indicates that p38 MAP kinase plays a pivotal role in AD 
pathophysiology and its inhibitors offer benefits to AD patients [43, 84]. Higher levels of 
phosphorylated p38 were reported in AD cybrids [24, 38], however, the involvement of p38 
in mitochondrial dysfunction and oxidative stress in AD remains unknown. The link of AD 
mitochondria-mediated activation of p38/ROS to synaptogenesis is poorly understood. By 
applying a recognized inhibitor of p38 MAP kinase, SB203580, we provide the direct 
evidence that activation of p38 MAP kinase signaling pathway contributes to mitochondrial 
dysfunction in differentiated AD cybrids. In addition, we demonstrated that inhibition of p38 
MAP kinase activation significantly reduced mitochondrial and cellular ROS levels and 
improved mitochondrial function, resulting in normal differentiation and synaptic 
development in the differentiated AD cybrids. To clarify, Fig. 4 showed levels of phospho-
p38 kinase in both AD and non-AD cybrid cells under a low concentration of staurosporine 
(10 nM)-induced differentiation. The phospho-p38 levels were significantly elevated by ~2.5 
fold in AD cybrid cells compared to non-AD cybrid cells, suggesting AD-associated 
activation of p38 kinase in AD cybrid cells may not fully depend on staurosporine-induced 
p38 MAP kinase activation. These data suggest the role of p38 on AD mitochondrial defects 
and oxidative stress. However, whether other MAP kinase pathways, such as c-Jun N-
terminal kinase (JNK) [85, 86] and extracellular signal-regulated protein (ERK) [18, 87], 
may also be involved in AD-mediated aberrant neuronal differentiation and synaptic 
formation.
In summary, we have demonstrated that AD mitochondrial defects contribute to synaptic 
deficiency in differentiated AD-cybrids. The mitochondrial dysfunction and abnormally 
elevated mitochondrial oxidative stress are responsible for the synaptic alteration through the 
activation of p38 MAP kinase signaling pathway. Importantly, blockade p38 MAP kinase 
activation by pharmaceutical inhibitor not only improves mitochondrial function and 
suppresses oxidative stress, but also restores the neuronal differentiation and the formation 
of synapses in cybrid cells containing AD mitochondria. Thus, modulating MAP kinase 
signaling pathway could be a therapeutical intervention in protection against early synaptic 
deficiency associated with memory loss and cognitive decline, and thereby defeating AD at 
an early stage. Furthermore, the outcomes of studying AD-derived mitochondria using 
human AD cybrid cells as an ex-vivo model, can be interpreted more meaningfully to the 
sporadic AD-specific mitochondrial defects because clinical data are available for the 
proposed AD cases, which significantly enhances our understanding of the AD pathogenesis 
and exploring the therapeutic strategy.
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Comparison of differentiation status in neuronal processes between non-AD and AD cybrid 
cells during differentiation. A) Representative morphological images from non-AD and AD 
cybrid cells under undifferentiated conditions or induced by SAT (14 days after 10 nM 
staurosporine [SAT] treatment). Scale bar = 50 μm. B) Quantification of neuronal process 
length of cybrid cells using the image J program. Black bars denote the process length of 
cybrid cells following SAT treatment in both non-AD and AD groups. Open bars represent 
process lengths of undifferentiated cybrid cells without SAT treatment.
Yu et al. Page 19














Expression of neuronal markers in non-AD and AD cybrid cells during differentiation. 
Immunoblotting of protein extracts from non-AD and AD cybrid cells for MAP2 (A) and 
NeuN (B) in the indicated groups of cells. β-actin was used for protein loading control. The 
upper panel displays quantification of immunoreactive bands for the corresponding protein 
relative to β-actin. Data are expressed as fold increase relative to undifferenciated non-AD 
cybrid cells. Quantification of fluorescent intensity of MAP2 (C) and NeuN (D), and (E), 
representative images of immunofluorescent staining for MAP2 (green) and NeuN (red) in 
the indicated groups of cybrid cells. Scale bar = 50 μm.
Yu et al. Page 20














Expression of synaptic proteins in AD cybrid cells during differentiation. A) 
Immunoblotting of protein extracts from non-AD and AD cybrid cells for PSD95 and 
synaptophysin in the indicated groups of cells. β-actin was used for protein loading control. 
The upper panel displays quantification of immunoreactive bands for the corresponding 
protein relative to β-actin. Data are expressed as fold increase relative to undifferentiated 
non-AD cybrid cells. Quantification of fluorescent intensity of synaptophysin (B) and 
PSD95 (C). Representative images of immunofluorescent staining for synaptophysin (red) 
and PSD95 (green) in the indicated groups of cybrid cells (D). Scale bars = 50 μm.
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Effect of p38 signaling pathway and its inhibitor on neuronal differentiation and expression 
of synaptic proteins in AD cybrid cells during differentiation. A) Immunoblotting of protein 
extracts from non-AD and AD cybrid cells for p-p38 and t-p-38 in the indicated groups of 
cells. β-actin was used for protein loading control. The upper panel displays quantification 
of immunoreactive bands for the corresponding protein relative to β-actin. Data are 
expressed as fold increase relative to non-AD vehicle cybrid cells. Open bars represent the 
protein expression level of p-p38 in the indicated groups of cybrid cells without any 
treatment. Black bars denote the protein expression level of p-p38 in the indicated groups of 
cybrid cells with the treatment of SB203580. Scale bar = 50 μm. B) Representative 
morphological images of mitochondria in the processes of above differentiated non-AD and 
AD cybrid cells (I–IV). I and II: non-AD and AD cells under differentiation without any 
treatment. III and IV: non-AD and AD cybrid cells under differentiation with the addition of 
the inhibitor of P38, SB203580. C) Quantification of neuronal process length of cybrid cells 
using the image J program. D) Immunoblotting of protein extracts from differentiated non-
AD and AD cybrid cells with or without SB203580 treatment for MAP2 and NeuN. β-actin 
was used for protein loading control. The upper panel displays quantification of 
immunoreactive bands for the corresponding protein relative to β-actin. Data are expressed 
as fold increase relative to non-AD vehicle cybrid cells. Open bars represent the protein 
expression level of MAP2 in the indicated groups of cybrid cells. Black bars denote the 
protein expression level of NeuN in the indicated groups of cybrid cells. E) Immunoblotting 
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of protein extracts from differentiated non-AD and AD cybrid cells with or without 
SB203580 treatment for PSD95 and Synaptophysin. β-actin was used for protein loading 
control. The upper panel displays quantification of immunoreactive bands for the 
corresponding protein relative to β-actin. Data are expressed as fold increase relative to non-
AD vehicle cybrid cells.
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Effect of p38 MAP kinase pathway and its inhibitor on mitochondrial function and ROS in 
AD cybrid cells during differentiation. Mitochondrial ROS levels were measured by 
MitoSox staining intensity (A and B) and generation of ROS in the indicated groups of cells 
was detected by electron paramagnetic resonance (EPR) spectra (C–D). Enzymatic activity 
of complex IV (E), and cellular ATP levels (F) were determined in cell lysates from 
differentiated AD cybrid cells with or without the addition of SB203580. Data were 
expressed as fold increase relative to AD cybrid cells without the addition of SB203580 
(vehicle treatment). Mitochondrial membrane potential was measured by TMRM staining 
intensity (G and H). Quantifications of immunofluorescent intensity for MitoSox (A), the 
signal intensity of EPR (C), and TMRM (G) in mitochondria of the indicated cybrid cells. 
The representative EPR and staining images were shown for EPR (D), and red fluorescence 
for Mitosox (B) and TMRM (H). Data were collected from 20–25 processes of each AD 
cybrid cell line with different treatments. Scale bars = 25 μm.
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Schematic depiction of p38 MAP kinase pathway in response to elevated ROS levels and 
mitochondrial dysfunction, leading to arrested differentiation and synaptic deficits in AD 
cybrid cells. Meanwhile, activated p38 MAP kinase pathway in turn promotes ROS 
production and augments mitochondrial dysfunction, eventually exacerbates the impaired 
differentiation and synaptic deficits in AD cybrid cells. Thus, blocking p38 MAPK 
activation using a pharmacological inhibitor of p38 MAPK (SB203580) could reverses AD 
mitochondria-mediated detrimental effects by suppressing ROS production and 
accumulation, powering mitochondrial function, and maintaining normal differentiation and 
synaptic development.
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